Home > News

 

 

ARCHIVE NEWS
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
27 November 2020
World Prematurity Day: Chiesi is at the forefront for preterm babies
17 November 2020
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
02 November 2020
Regeneration 20|3, the first global meeting to launch the program is in Parma on October 15 and 16.
06 October 2020
Italy for Climate: Chiesi at the forefront for the future of Italy
01 October 2020
CHIESI JOINS THE MOVEMENT OF ITALIAN B CORP COMPANIES “UNLOCK THE CHANGE”
20 July 2020
The B Change: the Instant Book by Pharmastar is online
14 July 2020
Chiesi Group and Holostem Terapie Avanzate announce transfer of Holoclar® from the Chiesi Group to Holostem
16 June 2020
Happiness&Wellbeing: Maria Paola Chiesi at the Vatican workshop
29 May 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
28 May 2020
© 2025 CHIESI Farmaceutici S.p.A.
VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE


follow us on: